Episode 3

Victor Bustos, Refoxy Pharma

Published on: 19th February, 2026

Why does the perception of facts matter when talking to investors?

How do you attract a US-based chair to a European company’s board?

And what are the advantages of running a virtual biotech with no labs of its own?

Today, I’m joined by Victor Bustos, CEO of Refoxy Pharma. Refoxy is a "virtual biotech" located in Cologne, Germany, and is developing small-molecule drugs for the treatment of age-related disease.

About LifeScience ORG

It’s no secret that Europe is a global leader in generating translational science. We’re grateful at LifeScience ORG to have a community of over 400 life science CEOs – leaders driving change in biotech, medtech, techBio and healthcare.

The conversations inside our community – stories of conviction, navigating challenges, and making bold decisions – inspire us every week. To hear the stories, lessons, and experiences of our life science leaders, listen to A Call to Lead @ LifeScience ORG, available on all good podcasting platforms.


Timestamps:

0:00 - Introduction: The Leadership Journey

1:24 - From Academia to Entrepreneurship

6:00 - Early Leadership Challenges: Truth vs. Perception

7:24 - Communication Skills & Stakeholder Management

10:37 - Peer Learning & Strategic Thinking

12:05 - Building Your Board: Attracting US Talent to Europe

13:29 - Virtual Biotech Model: Advantages & Strategy

16:26 - Due Diligence in CRO Partnerships

18:09 - The Science: Targeting Age-Related Disease

20:01 - Strategic Indication Selection: IPF Case Study

22:01 - Ecosystem Collaboration & Regulatory Landscape

23:31 - The Future of Longevity Medicine

25:25 - Leadership Philosophy: Leading by Example

Next Episode All Episodes Previous Episode
Show artwork for A Call to Lead @LifeScience ORG

About the Podcast

A Call to Lead @LifeScience ORG
Sharing the leadership journeys of life science entrepreneurs shaping the future of healthcare.
A Call To Lead is a series shining a light on the leadership, vision, and impact of European life science CEOs who are proving that world-class ventures don’t need to be built in Boston to shape the future of healthcare.

Each episode features a one-on-one conversation with a European life science CEO and member of the LifeScience ORG community. Our conversations are not about companies or pipelines; instead, guests reflect on their personal journeys, the pivotal choices that shaped their careers, and the future they are helping to build. These kinds of insights are rarely shared publicly.

New episodes are released every Thursday.